D.D. for the next few qtr's 2013-2014
1)7th Vaccine & ISV Congress Sitges, Barcelon Spain 27-29 October 2013
Monday 28 October, 15:30-17:30
*Immunoadjuvant IL-33 enhances Human Papillomavirus 16 E6/E7-specific cell-mediated immunity and induced potent antitumor immunity
University of Pennsylvania, USA, 2Inovio Pharmaceuticals, Inc, USA
*Induction of potent CTL activity for cancer immunotherapy: Development of VGX-3100 for HPV associated cancers and hTERT DNA vaccine for solid tumors
J. Yan1, M.P. Morrow1, P. Pankhong2, T. Shin2, N. Obeng-Adjei2, J.N. Walters2, A.S. Khan1, M. Bagarazzi1, D.B. Weiner2, N.Y. Sardesai*1
1Inovio Pharmaceuticals, Inc., USA, 2University of Pennsylvnia, USA
*HIV-1 Env DNA Vaccine Plus Protein Boost Delivered By EP Expands B- And T-Cell Responses And Neutralizing Phenotype in vivo (poster)
K. Muthumani1, K. Broderick2, N. Hutnick1, M. Wise1, J. Yan2, J. Mendoza2, C. Tingey1, S. Flingai1, N. Sardesai2, D. Weiner*1
1University of Pennsylvania School of Medicine, USA, 2Inovio Pharmaceuticals Inc, USA
*Synthetic enhanced EP delivered Ig DNA vector drives biologically relevant Anti-HIV-1 envelope responses in Vivo
K. Muthumani1, S. Flingai1, M. Wise1, C. Tingey1, E. Reuschel1, K. Ugen2, D. Weiner*1
1Department of Pathology and Laboratory Medicine, USA, 2University of South Florida Morsani College of Medicine, USA
*The co-delivery of esx multivalent TB DNA vaccines with electroporation induces potent immune responses
(poster)
D.O. Villarreal*, D.B. Weiner
University of Pennsylvania, USA
2)Pennvax GP trial(launch coming before years expected pr in a few weeks)
3)DNA-based Influenza Vaccine in the Elderly
ClinicalTrials gov Identifier: (NCT01587131)
Secondary Outcome Measures:
Estimated Enrollment: 50
Study Start Date: June 2012
Estimated Study Completion Date:October 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
4)Mid November..expected update on institutional buying(discussions currently in progress)
5)NOV 25, 2013 Brean Capital Life Science Summit
New York, NY
6)Leukemia CML & AML Additional phase II data (2013
7) Biodefense projects dates are never listed but new work has been completes on the Lassa Virus and Puumala & Hantaan viruses as as recent as last month update should be coming before years end on one of the projects
8)DEC 3-4, 2013
Piper Jaffray Healthcare Conference
New York, NY
9)DEC 3-5, 2013
LD Micro Conference
Los Angeles, CA
10)PENNVAX-G DNA Vaccine
Estimated Enrollment: 92
Study Start Date: February 2010
Estimated Primary Completion Date:December 2013 (Final data collection date for primary outcome measure)
11) Malaria vaccine funded by path/mvi 1st qtr 2014 P1 trial launch
12)Cell & Gene Therapy Forum 2014, 27th–29th January
Cancer vaccines: Learning from past successes and failures to deliver
game-changing efficacy
2.30 Chair’s introduction
Dr Mark Bagarazzi, Chief Medical Officer, Inovio
Industry case studies
Latest clinical data from leading cancer vaccines in development
What progress is being made in developing a viable business model for autologous cancer
vaccines?
What have we learnt in terms of improving the potency of cancer vaccines?
13)6th Immunotherapeutics & Immunomonitoring (Jan 29, 2014 to Jan 31, 2014 San Diego, CA, USA)
10:55 DNA Delivery to Skin and Muscle is Enhanced by Next Generation Electroporation Devices and has Generated Clinically Relevant Immune Responses
Kate Broderick
Director, Research & Development
Inovio
The magnitude of the immune response to a DNA vaccine depends on three criteria - optimized vector design, optimized vaccine formulations with or without suitable molecular adjuvants and the successful delivery and subsequent expression of the DNA plasmid in the target tissue. In vivo electroporation (EP) is an efficient non-viral method for enhancing DNA vaccine delivery and immunogenicity.
Here, we discuss the use of EP in both animal models and human in the clinic and describe novel concepts for DNA delivery to target tissues such as the skin and muscle. We outline the combination of DNA vaccine and EP delivery to target both therapeutic and prophylactic diseases in both the infectious disease and oncological arenas.
VGX-3100 was developed as a two plasmid combination vaccine targeting the E6/E7 gene products of HPV-16 and 18 as an immune therapy for cervical dysplasia. Vaccination of humans with highly optimized HPV constructs delivered by CELLECTRA® EP device induces significant levels of both cellular and humoral responses.
DNA plasmids combined with EP device modalities may have important clinical applications for delivery of prophylactic and therapeutic vaccines against diseases such as HIV, malaria and tuberculosis that require both cellular and humoral immune responses for protection and elimination since this device offers a safe, tolerable and most importantly, potent method to administer DNA vaccines.
Day 1 - Thursday, January 30, 2014
14)VGX-3100 SynCon® vaccine for cervical dysplasia/cancer CIN 2/3
Phase II study enrollment completed; top-line data expected in mid-2014.
15)INO-5150 SynCon® immunotherapy for prostate cancer
phase I/IIa 1H 2014 (Roche Milestone payment also)
Many other projects are being launched 2014 including Breast/lung cancer INO-1400 hTERT,and hep B. Dr. Kim recently stated at the last conference investors can expect a few surprises before years end 2013. Pennvax B therapeutic update is expected soon by investors, but no guidance has been giving by management on that yet so we cant confirm a time frame.
